中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles

文献类型：期刊论文

作者Zhang, Wen7,8; Zhai, Yihui1,7; Cai, Ying1,7; Gong, Xiang7,8; Jiang, Yunxuan5; Rong, Rong4; Zheng, Chao7,8; Zhu, Binyu1,7; Zhu, Helen He2,3; Wang, Hao8
刊名ACTA PHARMACEUTICA SINICA B
出版日期2024-07-01
卷号14期号:7页码:3218-3231
关键词MHC-I deficiency Macrophage CD47 Immunotherapy Triple-negative breast cancer Phagocytosis Immune checkpoint Innate immunity
ISSN号2211-3835
DOI10.1016/j.apsb.2024.04.009
通讯作者Wang, Hao(wanghao99@hotmail.com) ; Li, Yaping(ypli@simm.ac.cn) ; Zhang, Pengcheng(zhangpch1@shanghaitech.edu.cn)
英文摘要Current cytotoxic T lymphocyte (CTL) activating immunotherapy requires a major histocompatibility complex I (MHC-I)-mediated presentation of tumor-associated antigens, which malfunctions in around half of patients with triple-negative breast cancer (TNBC). Here, we create a LCL161-loaded macrophage membrane decorated nanoparticle (LMN) for immunotherapy of MHC-I-deficient TNBC. SIRP a on the macrophage membrane helps LMNs recognize CD47-expressing cancer cells for targeted delivery of LCL161, which induces the release of high mobility group protein 1 and proinflammatory cytokines from cancer cells. The released cytokines and high mobility group protein 1 activate antitumor immunity by increasing the intratumoral density of the phagocytic macrophage subtype by 15 times and elevating the intratumoral concentration of CTL lymphotoxin by 4.6 folds. LMNs also block CD47- mediated phagocytosis suppression. LMNs inhibit the growth of MHC-I-deficient TNBC tumors, as well as those resistant to combined therapy of anti-PDL1 antibody and albumin-bound paclitaxel, and prolong the survival of animals, during which process CTLs also play important roles. This macrophage membrane-decorated nanoparticle presents a generalizable platform for increasing macrophage- mediated antitumor immunity for effective immunotherapy of MHC-I-deficient cancers. 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
资助项目National Natural Science Foundation of China[32371457] ; National Natural Science Foundation of China[32171374] ; National Natural Science Foundation of China[32130058] ; Shandong Laboratory Program[SYS202205]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001265457900001
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
源URL[http://119.78.100.183/handle/2S10ELR8/312231]  
专题新药研究国家重点实验室
通讯作者Wang, Hao; Li, Yaping; Zhang, Pengcheng
作者单位1.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
2.Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200127, Peoples R China
3.Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes,Renji Med, Shanghai 200127, Peoples R China
4.Yantai Inst Mat Med, Shandong 264000, Peoples R China
5.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
6.ShanghaiTech Univ, Sch Biomed Engn, State Key Lab Adv Med Mat & Devices, Shanghai 201210, Peoples R China
7.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res & Ctr Pharmaceut, Shanghai 201203, Peoples R China
8.China State Inst Pharmaceut Ind, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Zhang, Wen,Zhai, Yihui,Cai, Ying,et al. Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles[J]. ACTA PHARMACEUTICA SINICA B,2024,14(7):3218-3231.
APA Zhang, Wen.,Zhai, Yihui.,Cai, Ying.,Gong, Xiang.,Jiang, Yunxuan.,...&Zhang, Pengcheng.(2024).Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles.ACTA PHARMACEUTICA SINICA B,14(7),3218-3231.
MLA Zhang, Wen,et al."Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles".ACTA PHARMACEUTICA SINICA B 14.7(2024):3218-3231.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。